Company Overview

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on the development of therapeutics for fibro-inflammatory diseases with high unmet medical need. The company operates within the biotechnology and biopharmaceutical industries, with a primary focus on developing monoclonal antibody therapies targeting the soluble protein CCL24, a chemokine associated with fibrosis and inflammation. Chemomab’s lead product candidate, CM-101, is being evaluated for conditions including primary sclerosing cholangitis (PSC) and systemic sclerosis-associated interstitial lung disease (SSc-ILD), both of which currently have limited treatment options. The company primarily serves healthcare providers, specialty treatment centers, and future commercial markets in rare and chronic inflammatory diseases.

Chemomab was founded in Israel and later established a broader corporate presence through public market activity in the United States. The company became publicly traded on Nasdaq under the ticker CMMB following a business combination involving a special purpose acquisition company. Its strategic positioning is centered on targeting the CCL24 pathway, which the company believes may play a central role in fibrosis and inflammatory signaling across multiple organ systems. Data from clinical and preclinical studies have positioned CM-101 as the company’s primary value driver.

Business Operations

Chemomab’s operations are concentrated primarily within its therapeutic development platform and clinical-stage drug development activities. The company’s core business is organized around the advancement of its lead antibody candidate, CM-101, including clinical trials, regulatory engagement, manufacturing coordination, and translational research. Revenue generation has historically been limited, consistent with development-stage biotechnology companies, with funding primarily derived from capital raises, strategic financing transactions, and public market activities rather than commercial product sales.

The company operates internationally, with activities spanning Israel, the United States, and clinical research locations in additional regions. Chemomab controls intellectual property related to CCL24-targeting therapeutics and associated biologic technologies. The company has worked with contract research organizations, clinical trial operators, and manufacturing partners to support development activities. Public disclosures indicate collaboration with external academic and scientific institutions in fibrosis-related research, although no large-scale commercial joint venture structure has been prominently disclosed in public filings.

Strategic Position & Investments

Chemomab’s strategic direction is focused on advancing CM-101 through later-stage clinical development in fibro-inflammatory diseases while expanding the therapeutic relevance of CCL24 inhibition into additional indications. The company has emphasized orphan and rare disease markets where regulatory pathways may support accelerated development and where unmet medical need remains significant. Clinical trial progression in PSC has represented a major strategic priority due to the limited availability of approved therapies in that indication.

The company has invested substantially in biologics development, clinical trial infrastructure, and intellectual property protection related to fibrosis and immune-mediated disease mechanisms. Chemomab’s public filings and investor communications have highlighted interest in broader applications of chemokine modulation and immune-fibrotic pathways. Data inconclusive based on available public sources regarding any material portfolio-company holdings or large-scale acquisition activity, as Chemomab primarily operates as a focused clinical-stage biotechnology developer rather than a diversified holding entity.

Geographic Footprint

Chemomab maintains operational and corporate ties across multiple regions, with historical roots and research activity in Israel and a public-market presence in the United States through its Nasdaq listing. The company’s headquarters functions and executive leadership activities have included operations in both regions, reflecting its dual international orientation. Clinical development activities have involved research sites and partnerships extending into North America and other international clinical markets.

The company’s market presence is primarily concentrated in regions with advanced pharmaceutical regulatory systems and specialty care infrastructure relevant to rare disease therapeutics. While Chemomab does not currently maintain a broad commercial sales footprint due to its pre-commercial status, its development strategy is internationally oriented and designed to support eventual regulatory engagement across multiple jurisdictions.

Leadership & Governance

Chemomab’s leadership team combines biotechnology, clinical development, pharmaceutical commercialization, and financial management experience. Corporate governance has emphasized advancement of late-stage clinical assets, disciplined capital management, and scientific validation of the company’s fibrosis-focused platform. Public company governance practices are overseen through a board structure consistent with Nasdaq-listed biotechnology issuers.

Key executives associated with the company include:

• Adi Mor – Chief Executive Officer
• Yochi Slonim – Founder and Chief Scientific Officer
• Motti Geva – Chief Financial Officer
• Dror Harats, M.D. – Chairman of the Board

Leadership communications and corporate filings have consistently emphasized the strategic objective of establishing CM-101 as a differentiated therapy for rare fibro-inflammatory diseases while expanding the scientific understanding of the CCL24 signaling pathway. Data regarding additional executive appointments or governance changes may vary across reporting periods and should be interpreted in the context of the company’s most recent public filings.